Effective treatment with omalizumab of a patient with spontaneous chronic urticaria and eosinophilic esophagitis

Abstract

This article reports the clinical history of a patient who had been affected by chronic spontaneous urticaria for 13 years, resistant to currently recommended therapy, and who was also diagnosed eosinophilic esophagitis. The anti-IgE monoclonal antibody omalizumab was rapidly effective and induced the clinical remission of both diseases.

Keywords:

• Chronic spontaneous urticaria
• eosinophilic esophagitis
• omalizumab
• esophagogastroduodenoscopy

Acknowledgement

Medical writing assistance of this paper was provided by Laura Brogelli, on behalf of Content Ed Net; this assistance was funded by Novartis.

Patient consent

The patient gave consent to the inclusion of material pertaining herself into this article, she acknowledged that she cannot be identified via the paper; the Authors fully anonymized patient’s material.

Disclosure statement

No potential conflict of interest was reported by the authors.

Additional information

Funding

This supplement was funded by Novartis.